Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Authors

null

Georg Lenz

Translational Oncology Medical Clinic, Münster University Clinic, Münster, Germany

Georg Lenz , Eliza Hawkes , Gregor Verhoef , Corinne Haioun , Lim Soon Thye , Dae Seog Heo , Kirit Ardeshna , Geoffrey Chong , Jacob Haaber Christensen , Vivian Shi , Susanne Lippert , Florian Hiemeyer , Paolo Piraino , Carol Elaine Pena , Viktoriya Buvaylo , Barrett H. Childs , Igor Gorbatchevsky , Gilles A. Salles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02391116

Citation

J Clin Oncol 35, 2017 (suppl; abstr 7536)

DOI

10.1200/JCO.2017.35.15_suppl.7536

Abstract #

7536

Poster Bd #

298

Abstract Disclosures

Similar Posters

First Author: Mohamad Barakat

Poster

2020 Genitourinary Cancers Symposium

Genomic analysis for potential targetable mutations in relapsed and refractory germ cell tumors.

Genomic analysis for potential targetable mutations in relapsed and refractory germ cell tumors.

First Author: Sean Q. Kern